Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial

医学 安慰剂 双盲 内科学 物理疗法 儿科 病理 替代医学
作者
Benedikt Schoser,Mark Roberts,Barry J. Byrne,Sheela Sitaraman,Hai Jiang,Pascal Laforêt,António Toscano,Jeff Castelli,Jordi Díaz‐Manera,Mitchell Goldman,Ans T. van der Ploeg,Drago Bratkovic,Suresh V. Kuchipudi,Tahseen Mozaffar,Priya S. Kishnani,Ágnes Sebők,Alan Pestronk,Aleksandra Dominović-Kovačević,Anzalee Khan,Blaž Koritnik,Céline Tard,Christopher Lindberg,Colin Quinn,Cornelia Kornblum,Crystal Eldridge,Cynthia Bodkin,David Reyes‐Leiva,Derralynn Hughes,Ela Stefanescu,Emmanuelle Salort‐Campana,Ernest Butler,Françoise Bouhour,Gee Kim,George K. Papadimas,Giancarlo Parenti,Halina Bartosik-Psujek,Hani Kushlaf,Akihiro Hashiguchi,Heather Lau,Hélio Pedro,Henning Andersen,Hernán Amartino,Hideaki Shiraishi,Hiroshi Kobayashi,Ivaylo Tarnev,Jaime Vengoechea,Jennifer Avelar,Jin‐Hong Shin,Jonathan Cauci,Jorge Alonso‐Pérez,József Janszky,Julie Berthy,Kristina Gutschmidt,Kristl G. Claeys,Mária Judit Molnár,Marie Wencel,Mark A. Tarnopolsky,Mazen M. Dimachkie,Michel Tchan,Miriam Freimer,Nicola Longo,Nuria Vidal-Fernandez,Olimpia Musumeci,Özlem Göker-Alpan,Patrick Deegan,Paula R. Clemens,Richard Roxburgh,Robert Henderson,Robert J. Hopkin,Sabrina Sacconi,Simona Fecarotta,Shahram Attarian,Stephan Wenninger,Stephanie DeArmey,Tarekegn Hiwot,Thomas Andrew Burrow,Tobias Ruck,Tomo Sawada,Vescei Laszlo,Wolfgang N. Löscher,Yin‐Hsiu Chien
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:20 (12): 1027-1037 被引量:75
标识
DOI:10.1016/s1474-4422(21)00331-8
摘要

Pompe disease is a rare disorder characterised by progressive loss of muscle and respiratory function due to acid α-glucosidase deficiency. Enzyme replacement therapy with recombinant human acid α-glucosidase, alglucosidase alfa, is the first approved treatment for the disease, but some patients do not respond, and many do not show a sustained benefit. We aimed to assess the safety and efficacy of an investigational two-component therapy (cipaglucosidase alfa, a novel recombinant human acid α-glucosidase, plus miglustat, an enzyme stabiliser) for late-onset Pompe disease.We did a randomised, double-blind, parallel-group, phase 3 trial at 62 neuromuscular and metabolic medical centres in 24 countries in the Americas, Asia-Pacific, and Europe. Eligible participants were aged 18 years or older with late-onset Pompe disease, and had either been receiving alglucosidase alfa for at least 2 years or were enzyme replacement therapy-naive. Participants were randomly assigned (2:1) using interactive response technology software, stratified by 6-min walk distance and previous enzyme replacement therapy status, to intravenous cipaglucosidase alfa (20 mg/kg) plus oral miglustat or to intravenous alglucosidase alfa (20 mg/kg) plus oral placebo once every 2 weeks for 52 weeks. Patients, investigators, and outcome assessors were masked to treatment assignment. The primary endpoint was change from baseline to week 52 in 6-min walk distance, assessed using a mixed-effect model for repeated measures analysis for comparison of superiority in the intention-to-treat population (all patients who received at least one dose of study drug). This study is now complete and is registered with ClinicalTrials.gov, NCT03729362.Between Dec 3, 2018, and Nov 26, 2019, 130 patients were screened for eligibility and 125 were enrolled and randomly assigned to receive cipaglucosidase alfa plus miglustat (n=85) or alglucosidase alfa plus placebo (n=40). Two patients in the alglucosidase alfa plus placebo group did not receive any dose due to absence of genotype confirmation of late-onset Pompe disease and were excluded from analysis. Six patients discontinued (one in the alglucosidase alfa plus placebo group, five in the cipaglucosidase alfa plus miglustat group), and 117 completed the study. At week 52, mean change from baseline in 6-min walk distance was 20·8 m (SE 4·6) in the cipaglucosidase alfa plus miglustat group versus 7·2 m (6·6) in the alglucosidase alfa plus placebo group using last observation carried forward (between-group difference 13·6 m [95% CI -2·8 to 29·9]). 118 (96%) of 123 patients experienced at least one treatment-emergent adverse event during the study; the incidence was similar between the cipaglucosidase alfa plus miglustat group (n=81 [95%]) and the alglucosidase alfa plus placebo group (n=37 [97%]). The most frequently reported treatment-emergent adverse events were fall (25 [29%] patients in the cipaglucosidase alfa plus miglustat group vs 15 [39%] in the alglucosidase alfa plus placebo group), headache (20 [24%] vs 9 [24%]), nasopharyngitis (19 [22%] vs 3 [8%]), myalgia (14 [16%] vs 5 [13%]), and arthralgia (13 [15%]) vs 5 [13%]). 12 serious adverse events occurred in eight patients in the cipaglucosidase alfa plus miglustat group; only one event (anaphylaxis) was deemed related to study drug. One serious adverse event (stroke) occurred in the alglucosidase alfa plus placebo group, which was deemed unrelated to study drug. There were no deaths.Cipaglucosidase alfa plus miglustat did not achieve statistical superiority to alglucosidase alfa plus placebo for improving 6-min walk distance in our overall population of patients with late-onset Pompe disease. Further studies should investigate the longer-term safety and efficacy of cipaglucosidase alfa plus miglustat and whether this investigational two-component therapy might provide benefits, particularly in respiratory function and in patients who have been receiving enzyme replacement therapy for more than 2 years, as suggested by our secondary and subgroup analyses.Amicus Therapeutics.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
hopen完成签到 ,获得积分10
1秒前
丘比特应助SS采纳,获得10
3秒前
月亮moon完成签到,获得积分10
3秒前
4秒前
充电宝应助qqq采纳,获得10
7秒前
顾矜应助lihan采纳,获得10
7秒前
爆米花应助周em12_采纳,获得10
8秒前
9秒前
三物完成签到 ,获得积分10
10秒前
jolt发布了新的文献求助10
11秒前
13秒前
13秒前
14秒前
momo发布了新的文献求助10
15秒前
量子星尘发布了新的文献求助30
15秒前
16秒前
17秒前
17秒前
善学以致用应助笃定采纳,获得30
18秒前
SS发布了新的文献求助10
20秒前
20秒前
ZZZ发布了新的文献求助10
20秒前
Justtry发布了新的文献求助20
22秒前
22秒前
顾矜应助momo采纳,获得10
23秒前
23秒前
hnlgdx发布了新的文献求助20
23秒前
25秒前
重要冷之完成签到,获得积分20
25秒前
25秒前
28秒前
VV完成签到,获得积分10
28秒前
ccalvintan发布了新的文献求助10
29秒前
蛋挞发布了新的文献求助10
30秒前
小马甲应助SS采纳,获得10
33秒前
XX完成签到,获得积分10
36秒前
37秒前
38秒前
慕青应助诚心的扬采纳,获得10
42秒前
zlttt发布了新的文献求助10
43秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989297
求助须知:如何正确求助?哪些是违规求助? 3531418
关于积分的说明 11253893
捐赠科研通 3270097
什么是DOI,文献DOI怎么找? 1804884
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809158